Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlphaRx has announced positive pre-clinical data on Zysolin, a Tobramycin compound encapsulated in the company's nano drug delivery platform intended for the treatment of cystic fibrosis and an adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients.
Subscribe to our email newsletter
In the recent animal study, the therapeutic efficacy of Zysolin was investigated in a mouse model of Pseudomonas aeruginosa pneumonia. In this acute model, pneumonia developed rapidly, resulting in a high mortality rate, no mice survived after 24 hours of infection without treatment.
Mice treated with Zysolin showed significantly better efficacy than Tobramycin, achieving 60% survival rate compared to 40% in the Tobramycin treatment group. An increase of survival by 50% or more, relative to vehicle control, indicates significant anti-microbial effect. The Tobramycin treatment group did not meet the study’s end point.